Age
|
-0.0032 (-0.0219; 0.0155)
|
0.7354
|
-0.0008 (-0.0120; 0.0105)
|
0.8961
|
-0.0149 (-0.0325; 0.0027)
|
0.0968
|
CCI
|
0.2529 (0.0572; 0.4486)
|
0.0113
|
0.0448 (0.0087; 0.0810)
|
0.0151
|
0.0747 (0.0182; 0.1312)
|
0.0096
|
Gender (male as reference)
|
Female
|
NA
| |
-0.1815 (-0.4202; 0.0573)
|
0.1363
|
-0.0132 (-0.3975; 0.3711)
|
0.9463
|
Days with cyclophosphamide (in breast cancer) or carboplatin (in lung cancer) treatment
|
-0.3800 (-0.5600; -0.2000)
|
<.0001
|
-0.0483 (-0.0848; -0.0118)
|
0.0095
|
0.0113 (-0.0263; 0.0488)
|
0.5561
|
Antiemetic regimen (older 5-HT3 RAs as reference)
|
Palonosetron
|
-0.6431 (-1.0391; -0.2471)*
|
0.0015
|
-0.3436 (-0.5871; -0.1001)*
|
0.0057
|
-0.0373 (-0.4456; 0.3711)
|
0.8580
|